LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment

The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.

The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use.

Named Patient Use (NPU)

Study Overview

• Status: Approved for marketing
• Conditions: Carcinoma, Non-Small-Cell Lung
• Intervention / Treatment: Drug: BIBW 2992

• Study Type: Expanded Access

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • North Ryde, New South Wales, Australia
      • 1200.47.1 Boehringer Ingelheim Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Patients with pathologic confirmation of adenocarcinoma of the lung Stage IIIB with pleural effusion or Stage IV

Exclusion criteria:

• Brain metastases which are symptomatic; patients with treated, asymptomatic brain metastases are eligible with stable brain disease for at least four 4 weeks without the requirement for steroids or anti epileptic therapy
• Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom as judged by the investigator.
• Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug
• History of cardiac disease that is clinically significant, as judged by the investigator or uncontrolled cardiac disease (including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3)
• Cardiac left ventricular function with resting ejection fraction of less than 50%
• Bilirubin 1.5 mg / dl (26 mol / L, SI unit equivalent)
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) three times the upper limit of normal (if related to liver metastases five times the upper limit of normal)
• Serum creatinine 1.5 times of the upper normal limit or calculated/measured creatine clearance 45ml/min
• Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial
• Pregnancy or breast feeding
• Patients unable to comply with the protocol
• Patients with known HIV, active hepatitis B or active hepatitis C
• Pre-existing Interstitial Lung Disease (ILD)
• Requirement for treatment with any of the prohibited concomitant medications listed in Section 4.2.2.1.
• Patients already pre-treated with BIBW 2992

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Study record dates

Study Registration Dates

• First Submitted: September 24, 2010
• First Submitted That Met QC Criteria: September 24, 2010
• First Posted (Estimate): September 27, 2010

Study Record Updates

• Last Update Posted (Estimate): November 10, 2016
• Last Update Submitted That Met QC Criteria: November 9, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Afatinib
• Other Study ID Numbers: 1200.47